SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced the launch of the
first clinically approved, highly-sensitive in-situ hybridisation (ISH) test,
the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries
accepting the CE Mark. The test helps differentiate a B-cell cancer from a
normal, reactive immune response.

B-cell lymphoma is a type of cancer that typically develops in the lymphatic
system. It accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL)
cases.

Roche noted that the new test enables assessment across the more than 60 B-cell
lymphoma subtypes and plasma cell neoplasms on a single tissue slide. The test
can assess small biopsies and formalin-fixed tissue, reducing the need for a
fresh tissue sample, which may not be available especially if lymphoma was not
originally suspected.

The company said the test properties preserve tissue, may result in fewer
additional patient biopsies and make interpretation quicker and easier for the
pathologist, helping create a faster diagnosis and access to treatment for
patients.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX